Your browser doesn't support javascript.
loading
HLA-E*01:01 allele is associated with better response to anti-HCV therapy while homozygous status for HLA-E*01:03 allele increases the resistance to anti-HCV treatments in frequently transfused thalassemia patients.
Hosseini, Ehteramolsadat; Sarraf Kazerooni, Ehsan; Azarkeivan, Azita; Sharifi, Zohreh; Shahabi, Majid; Ghasemzadeh, Mehran.
Afiliación
  • Hosseini E; Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Tehran, Iran.
  • Sarraf Kazerooni E; Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Tehran, Iran.
  • Azarkeivan A; Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Tehran, Iran; Iranian Blood Transfusion Organization, Thalassemia Clinic, Tehran, Iran.
  • Sharifi Z; Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Tehran, Iran.
  • Shahabi M; Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Tehran, Iran.
  • Ghasemzadeh M; Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Tehran, Iran. Electronic address: mehran1476@yahoo.com.
Hum Immunol ; 83(7): 556-563, 2022 Jul.
Article en En | MEDLINE | ID: mdl-35570067
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Talasemia / Antígenos de Histocompatibilidad Clase I / Hepatitis C / Hepatitis C Crónica Tipo de estudio: Risk_factors_studies Límite: Humans Idioma: En Revista: Hum Immunol Año: 2022 Tipo del documento: Article País de afiliación: Irán Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Talasemia / Antígenos de Histocompatibilidad Clase I / Hepatitis C / Hepatitis C Crónica Tipo de estudio: Risk_factors_studies Límite: Humans Idioma: En Revista: Hum Immunol Año: 2022 Tipo del documento: Article País de afiliación: Irán Pais de publicación: Estados Unidos